

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

blicant

Goddard, et al.

App. No

10/063,570

Filed

May 2, 2002

For

SECRETED AND

TRANSMEMBRANE POLYPEPTIDES

AND NUCLEIC ACIDS ENCODING

THE SAME

Examiner

Hunnicutt, Rachel Kapust

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 22, 2005

(Date)

Marc T. Morley, Reg. No. 52,051

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing nineteen (19) references to be considered by the Examiner. Also enclosed are nineteen (19) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

Please place these references in the file of the above-identified patent application in accordance with 37 C.F.R. § 1.97(i).

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 22, 2005

Marc T. Morley Registration No. 52,051

Attorney of Record

Customer No. 30,313

(619) 235-8550

PTO/SB/08 Equivalent

CODEICN	DATENT DOCUMENTS		
<i>a</i>			
SHEET 1 OF 2	Attorney Docket No.	GNE.3230R1C50	
B B Multiple sheets used when necessary)	Examiner	Hunnicutt, Rachel Kapust	
	Art Unit	1647	
CTATEMENT BY ADDITIONAL	First Named Inventor	Goddard, Audrey	
INFORMATION DISCLOSURE	Filing Date	May 2, 2002	
	Application No.	10/063,570	
	Application No.	10/063,570	

	•	~ <u>\$</u>				
JUL 2:	2005	1)CE	FOREIGN PATI	ENT DOCUMENTS		
	Cite	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	1	WO 97/38085	10-16-1997	California Pacific Medical Center		
	· · · · · · · · · · · · · · · · · · ·	NON	PATENT LITE	RATURE DOCUMENTS		
Examiner	Cite	Include name of the author (in		ΓERS), title of the article (wh		T <sup>1</sup>

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>	
	2	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. Blood, 87(12):5257-5268.		
	3	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular &amp; Cellular Proteomics 1.4</i> , pp. 304-313.		
	4	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.		
•	5	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	a.	
	6	GÖKMEN-POLAR, et al. 2001. Elevated protein kinase C ßII is an early promotive event in colon carcinogenesis. <i>Cancer Research</i> , 61:1375-1381.		
,	7	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.		
	8	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.		
	9	HANCOCK, W. S. 2004. Do we have enough biomarkers? Journal of Proteome Research, 3(4):685.		
	10	HAYNES, et al. 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , 19:1862		
	11	HU, et al. 2003. Analysis of genomic and proteomic data using advanced literature mining. <i>Journal of Proteome Research</i> , 2:405		
	12	JANG, et al. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastatis		
	13	KONOPKA, et al. 1986. Variable expression of the translocated c		
	14	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.		
	15	POWELL, et al. 1998. Expression of cytochrome P4502E1 in human liver: Assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , 8:411		
	16	TOKUNAGA, et al. 2000. Application of quantitative RT		

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance and not considered. Include copy of this form with next con	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

	Application No.	10/063,570
INFORMATION DISCLOSURE	Filing Date	May 2, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard, Audrey
	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Hunnicutt, Rachel Kapust
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C50
<u> </u>		

ſ	ım 2 5 200	NON PATENT LITERATURE DOCUMENTS		
Examiner Initials			Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	17		VALLEJO, et al. 2000. Evidence of tissue	
		18	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276	!
		19	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	

1826981 sma072105

**Examiner Signature** 

**Date Considered** 

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.